Seer (SEER) Competitors $2.36 +0.03 (+1.29%) Closing price 01/30/2025 04:00 PM EasternExtended Trading$2.36 +0.00 (+0.17%) As of 01/30/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SEER vs. EYPT, ALNT, QTRX, AEHR, QSI, NAUT, KEQU, FEIM, AKYA, and INTTShould you be buying Seer stock or one of its competitors? The main competitors of Seer include EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Quanterix (QTRX), Aehr Test Systems (AEHR), Quantum-Si (QSI), Nautilus Biotechnology (NAUT), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Akoya Biosciences (AKYA), and inTEST (INTT). These companies are all part of the "measuring and control equipment" industry. Seer vs. EyePoint Pharmaceuticals Allient Quanterix Aehr Test Systems Quantum-Si Nautilus Biotechnology Kewaunee Scientific Frequency Electronics Akoya Biosciences inTEST Seer (NASDAQ:SEER) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Does the MarketBeat Community prefer SEER or EYPT? EyePoint Pharmaceuticals received 462 more outperform votes than Seer when rated by MarketBeat users. Likewise, 70.24% of users gave EyePoint Pharmaceuticals an outperform vote while only 13.64% of users gave Seer an outperform vote. CompanyUnderperformOutperformSeerOutperform Votes313.64%Underperform Votes1986.36% EyePoint PharmaceuticalsOutperform Votes46570.24% Underperform Votes19729.76% Do institutionals and insiders believe in SEER or EYPT? 75.2% of Seer shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 15.0% of Seer shares are owned by insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is SEER or EYPT more profitable? EyePoint Pharmaceuticals has a net margin of -226.57% compared to Seer's net margin of -565.83%. Seer's return on equity of -21.96% beat EyePoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Seer-565.83% -21.96% -19.85% EyePoint Pharmaceuticals -226.57%-43.01%-31.63% Do analysts rate SEER or EYPT? Seer currently has a consensus target price of $3.00, indicating a potential upside of 27.12%. EyePoint Pharmaceuticals has a consensus target price of $26.63, indicating a potential upside of 230.75%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than Seer.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seer 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00EyePoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SEER or EYPT? In the previous week, Seer had 12 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 19 mentions for Seer and 7 mentions for EyePoint Pharmaceuticals. EyePoint Pharmaceuticals' average media sentiment score of 0.71 beat Seer's score of 0.29 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral EyePoint Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SEER or EYPT? Seer has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Which has stronger earnings & valuation, SEER or EYPT? EyePoint Pharmaceuticals has higher revenue and earnings than Seer. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeer$16.66M8.35-$86.28M-$1.30-1.82EyePoint Pharmaceuticals$46.02M11.94-$70.79M-$2.00-4.03 SummaryEyePoint Pharmaceuticals beats Seer on 11 of the 18 factors compared between the two stocks. Get Seer News Delivered to You Automatically Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEER vs. The Competition Export to ExcelMetricSeerAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.17M$5.89B$5.61B$9.12BDividend YieldN/A0.41%5.36%3.98%P/E Ratio-1.8230.9889.7717.51Price / Sales8.354.911,229.1083.39Price / CashN/A42.0144.3037.67Price / Book0.382.525.124.72Net Income-$86.28M$2.94M$117.86M$224.62M7 Day Performance-2.07%-0.41%1.84%-0.42%1 Month Performance3.96%5.09%7.95%3.57%1 Year Performance34.86%-21.97%26.54%19.11% Seer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEERSeer2.1371 of 5 stars$2.36+1.3%$3.00+27.1%+34.9%$139.17M$16.66M-1.82160EYPTEyePoint Pharmaceuticals1.6229 of 5 stars$8.02-6.0%$26.63+232.0%-68.8%$547.37M$46.02M-4.01120Short Interest ↑ALNTAllient4.2925 of 5 stars$25.62-3.8%$29.33+14.5%-11.4%$431.44M$578.63M29.112,287Short Interest ↓Positive NewsQTRXQuanterix2.2615 of 5 stars$9.58+0.1%$23.25+142.7%-58.3%$369.02M$122.37M-9.04460AEHRAehr Test Systems3.2767 of 5 stars$11.88-4.3%$25.00+110.4%-28.2%$352.96M$66.22M15.8490Gap DownQSIQuantum-Si2.9699 of 5 stars$2.21-3.9%$3.25+47.1%+18.8%$315.40M$2.27M-3.45150Short Interest ↓Gap UpNAUTNautilus Biotechnology3.1138 of 5 stars$1.84-4.2%$3.58+94.7%-39.2%$231.04MN/A-3.29130Short Interest ↓Positive NewsKEQUKewaunee Scientific1.5628 of 5 stars$58.45-4.1%N/A+124.3%$167.87M$199.64M9.261,006Short Interest ↓Positive NewsFEIMFrequency Electronics2.2947 of 5 stars$17.15-5.0%N/A+64.8%$164.81M$55.27M20.91200Short Interest ↑AKYAAkoya Biosciences2.3448 of 5 stars$3.08+0.3%$5.43+76.3%-39.6%$152.69M$86.82M-2.6190Short Interest ↑INTTinTEST2.217 of 5 stars$8.61-3.0%$16.00+85.8%-29.1%$106.59M$123.30M37.44320 Related Companies and Tools Related Companies EyePoint Pharmaceuticals Alternatives Allient Alternatives Quanterix Alternatives Aehr Test Systems Alternatives Quantum-Si Alternatives Nautilus Biotechnology Alternatives Kewaunee Scientific Alternatives Frequency Electronics Alternatives Akoya Biosciences Alternatives inTEST Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEER) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seer, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
